Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 10/20 | 0.79 |
| ▸ | NOS1 | P29475 | 9/20 | 0.67 |
| ▸ | NOS3 | P29474 | 5/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | DDAH1 | O94760 | 6/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13484050 | 1.00 | NOS2 (0.79) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL995818 | 1.00 | NOS2 (0.79) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL14843061 | 1.00 | NOS2 (0.79) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL31436337 | 0.89 | NOS2 (0.68) | NOS2NOS1NOS3CYP2C19MEN1 | |
| Hydrochloric Acid SCHEMBL30114268 | 0.87 | NOS2 (0.66) | NOS2NOS1NOS3CYP2C19MEN1 | |
| L-Nio SCHEMBL15944942 | 0.80 | NOS2 (1.00) | NOS2NOS1NOS3CYP2C19MEN1 | |
| Arginine SCHEMBL43261 | 0.80 | NOS2 (1.00) | NOS2NOS1NOS3CYP2C19MEN1 | |
| Arginine SCHEMBL30577923 | 0.80 | NOS2 (1.00) | NOS2NOS1NOS3CYP2C19MEN1 | |
| Arginine SCHEMBL288835 | 0.80 | NOS2 (1.00) | NOS2NOS1NOS3CYP2C19MEN1 | |
| Arginine SCHEMBL288993 | 0.80 | NOS2 (1.00) | NOS2NOS1NOS3CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011774-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | ENTRADA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | claimed |
| EP-4359006-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | Entrada Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| WO-2023185709-A1 | MARKER COMBINATION FOR DIAGNOSING ADVANCED COLORECTAL TUMOR, AND APPLICATION THEREOF | 武汉迈特维尔医学科技有限公司 | 2023-10-05 | — | — | WO | claimed |
| WO-2023192510-A1 | β-CATENIN ANTIBODIES | ENTRADA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | ENTRADA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | claimed |
| WO-2022271818-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | ENTRADA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | claimed |
| CN-106370753-A | Identification and analysis method for coronary heart disease urine metabolic markers | 王喜军 | 2017-02-01 | — | — | CN | claimed |
| US-20260098262-A9 | COMPOUNDS AND METHODS FOR SKIPPING EXON 44 IN DUCHENNE MUSCULAR DYSTROPHY | ENTRADA THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260028630-A1 | HYBRID OLIGONUCLEOTIDES | ENTRADA THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250289851-A1 | CYCLIC PEPTIDES FOR DELIVERING THERAPEUTICS | ENTRADA THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250228953-A1 | INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES | ENTRADA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025125621-A1 | CANCER-ASSOCIATED PROTEIN-TARGETED STRONG OR COVALENTLY BINDING PRECURSOR COMPOUNDS AND RADIOTRACERS | RADIOVAXX GMBH (DE) | 2025-06-19 | — | — | WO | disclosed |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-06-28 | — | — | US | disclosed |
| US-20060035854-A1 | Compositions and methods for coating medical devices | GOLDSTEIN STEVEN | 2006-02-16 | — | — | US | disclosed |
| EP-0910301-A4 | COMPOSITIONS AND METHODS FOR COATING MEDICAL DEVICES | UNIV MICHIGAN (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6358699-B1 | REMOVING INTERFERING COMPONENTS FROM SAMPLE, CONTACTING WITH DIMETHYLARGININE DIMETHYLAMINO-HYDROLASE TO HYDROLYZE DIMETHYLARGININE TO CITRULLINE, SPECTROPHOTOMETRICALLY DETERMINING CITRULLINE | COOKE PHARMA | 2002-03-19 | — | — | US | disclosed |
| US-6143037-A | MEDICAL EQUIPMENT COATED WITH A BIOCOMPATIBLE AND BIODEGRADABLE POLMERIC MATRIX AND A NULEIC ACID | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0910301-A1 | COMPOSITIONS AND METHODS FOR COATING MEDICAL DEVICES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997047254-A1 | COMPOSITIONS AND METHODS FOR COATING MEDICAL DEVICES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028630-A1 | HYBRID OLIGONUCLEOTIDES | RNGTT, BCDIN3D, RNMT | NOS2 4732/4885NOS1 4621/4885NOS3 3842/4885 |
| US-20250228953-A1 | INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES | MAN1B1, RNASE1, ERAP1 | NOS2 4785/4885NOS1 4764/4885NOS3 4756/4885 |
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | NOS2 2084/4885NOS1 2445/4885NOS3 2929/4885 |
| US-20260098262-A9 | COMPOUNDS AND METHODS FOR SKIPPING EXON 44 IN DUCHENNE MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, UPF1 | NOS2 4699/4885NOS1 4569/4885NOS3 4351/4885 |
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | PRCP, TAP1, DNPEP | NOS2 4518/4885NOS1 4467/4885NOS3 4611/4885 |
| US-20250011774-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | CDR2, SMN1; SMN2, ATXN2 | NOS2 4568/4885NOS1 4745/4885NOS3 4787/4885 |
| US-20250289851-A1 | CYCLIC PEPTIDES FOR DELIVERING THERAPEUTICS | IAPP, LNPEP, CFTR | NOS2 3390/4885NOS1 3719/4885NOS3 3474/4885 |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | FOXM1, F3, RB1 | NOS2 874/4885NOS1 595/4885NOS3 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.